Abimbola Farinde, PharmD, PhD

All articles by Abimbola Farinde, PharmD, PhD

No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning

February 25, 2020

Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.

Next post in Lymphoma

Abimbola Farinde, PharmD, PhD

All articles by Abimbola Farinde, PharmD, PhD

No Change in Transplant Outcomes for DLBCL With Addition of Rituximab to Conditioning

Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma